Research programme: anti-cancer mRNA therapeutics - Moderna Therapeutics

Drug Profile

Research programme: anti-cancer mRNA therapeutics - Moderna Therapeutics

Alternative Names: MEDI 1191; mRNA 2095; mRNA-2752; mRNA-IL12-iTu-I-O; MT 004; MT-377; MT-380; MT-513

Latest Information Update: 02 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Moderna Therapeutics
  • Developer Onkaido Therapeutics
  • Class RNA
  • Mechanism of Action Protein synthesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 Jul 2018 MEDI 1191 and mRNA 2752 is still in Preclinical development for Cancer in the US (Moderna Therapeutics, July 2018)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 11 Jul 2018 Moderna announces intention to submit IND of mRNA 2752 to USFDA for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top